CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 61,737 enrolled
Drug / intervention
Sumatriptan/Naproxen combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01332500
NCT01332500N/ACompleted
CompareCT.gov

Treximet ™ Pharmacy Budget Impact Model Database Validation Study

GlaxoSmithKline·observational·Posted Apr 11, 2011·Updated May 30, 2017

In Brief

An observational study evaluating Sumatriptan/Naproxen combination and other oral triptans for Migraine Disorders. Completed, enrolled 61,737 participants.

Detailed Summary

The purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. NSAIDs, Opioids, Ergots) utilization among migraine suffers following initiation of Treximet ™ (sumatriptan/naproxen) compared with subjects initiating treatment with other orally available triptans. The study was used to validate the migraine-related prescription utilization patterns predicted by the Treximet ™ Budget Impact Model. The SourceLx dataset from the family of Wolters Kluwer databases was used for this analysis. The database contains 30% of prescription claims filled in the United States (US), approximately 160 million patient lives. The data has broad representative coverage at both the geographic and payment levels.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 11, 2011
Enrollment StartJul 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.2 years ago

Interventions

Sumatriptan/Naproxen combinationdrug

Sumatriptan and Naproxen Sodium

other oral triptansdrug

almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan